Fredrik Klevebro
A5050796430- Esophageal Cancer Research and Treatment
- Gastric Cancer Management and Outcomes
- Esophageal and GI Pathology
- Lung Cancer Diagnosis and Treatment
- Cardiac, Anesthesia and Surgical Outcomes
- Gastrointestinal Tumor Research and Treatment
- Metastasis and carcinoma case studies
- Pancreatic and Hepatic Oncology Research
- Enhanced Recovery After Surgery
- Multiple and Secondary Primary Cancers
- Nutrition and Health in Aging
- Gastroesophageal reflux and treatments
- Helicobacter pylori-related gastroenterology studies
- Tracheal and airway disorders
- Lung Cancer Treatments and Mutations
- Dysphagia Assessment and Management
- Hemodynamic Monitoring and Therapy
- Foreign Body Medical Cases
- Ultrasound in Clinical Applications
- Cardiac Structural Anomalies and Repair
- Diverticular Disease and Complications
- Delphi Technique in Research
- Intraperitoneal and Appendiceal Malignancies
- Congenital Diaphragmatic Hernia Studies
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
Karolinska University Hospital
2016-2025
Karolinska Institutet
2016-2025
Virginia Mason Medical Center
2019-2024
University Medical Center Utrecht
2024
St. James's Hospital
2023
Trinity College Dublin
2023
International Breast Cancer Study Group
2021
Seattle University
2019-2020
Fudan University Shanghai Cancer Center
2018
NeoRes I is a randomized phase II trial comparing neoadjuvant chemoradiotherapy with chemotherapy in the treatment of resectable cancer esophagus or gastroesophageal junction. Patients biopsy-proven adenocarcinoma squamous cell carcinoma, T1N1 T2-3N0-1 and M0-M1a (AJCC 6th ed.), were to receive three 3-weekly cycles cisplatin 100 mg/m2 day 1 fluorouracil 750 mg/m2/24 hours, days 1–5 without addition concurrent radiotherapy 40 Gy, 2 Gy/fraction, 5 week, followed by esophageal resection...
<h3>Importance</h3> Ninety-day mortality rates after esophagectomy are an indicator of the quality surgical oncologic management. Accurate risk prediction based on large data sets may aid patients and surgeons in making informed decisions. <h3>Objective</h3> To develop validate a model death within 90 days for cancer using International Esodata Study Group (IESG) database, largest existing prospective, multicenter cohort reporting standardized postoperative outcomes. <h3>Design, Setting,...
The optimal time to surgery (TTS) after neoadjuvant chemoradiotherapy (nCRT) for oesophageal cancer is unknown and has traditionally been 4-6 weeks in clinical practice. Observational studies have suggested better outcomes, especially terms of histological response, prolonged delay up 3 months nCRT. NeoRes II trial the first randomised compare standard TTS nCRT cancer.Patients with resectable, locally advanced were randomly assigned or 10-12 primary endpoint was complete response tumour...
The impact of cardiorespiratory comorbidity on operative outcomes after esophagectomy remains controversial. This study investigated the effect postoperative complications for patients treated esophageal or gastroesophageal junction cancer. A European multicenter cohort from five high-volume cancer centers including between 2010 and 2017 was conducted. respiratory function upon assessed. In total 1590 were included; 274 (17.2%) had comorbidity, 468 (29.4%) cardiac comorbidity. Respiratory...
Objective: To identify the most prevalent symptoms and those with greatest impact upon health-related quality of life (HRQOL) among esophageal cancer survivors. Background: Long-term symptom burden after esophagectomy, associations HRQOL, are poorly understood. Patients Methods: Between 2010 2016, patients from 20 European Centers who underwent surgery, were disease-free at least 1 year postoperatively asked to complete LASER, EORTC-QLQ-C30, QLQ-OG25 questionnaires. Specific questionnaire...
Abstract Background Large studies comparing totally minimally invasive oesophagectomy (TMIE) with laparoscopically assisted (hybrid) are lacking. Although randomized trials have compared TMIE open oesophagectomy, daily clinical practice does not always resemble the results reported in such trials. The aim of present study was to compare complications after invasive, hybrid and Ivor Lewis patients oesophageal cancer. Methods performed using data from International Esodata Study Group...
Objective: To determine the impact of surveillance on recurrence pattern, treatment, survival and health-related quality-of-life (HRQL) following curative-intent resection for esophageal cancer. Summary Background Data: Although therapies recurrent cancer may HRQL, protocols after primary curative treatment are varied inconsistent, reflecting a lack evidence. Methods: European iNvestigation SUrveillance Resection Esophageal was an international multicenter study consecutive patients...
Laparoscopic gastrectomy is increasingly used for the treatment of locally advanced gastric cancer but concerns remain whether similar results can be obtained compared to open gastrectomy, especially in Western populations. This study short-term postoperative, oncological and survival outcomes following laparoscopic versus based on data from Swedish National Register Esophageal Gastric Cancer.Patients who underwent surgery with curative intent adenocarcinoma stomach or gastroesophageal...
Abstract Background The standard treatment for advanced gastric cancer without metastasis is gastrectomy in combination with chemotherapy. Some patients cannot tolerate such because of old age or comorbidities. In this study, we want to test the feasibility Laparoscopic and Endoscopic Cooperative Surgery (LECS) as a less invasive option. LECS, tumor margin marked endoscopically, followed by surgical removal under endoscopic guidance. Currently, LECS primarily used Asian countries...
Abstract Background Many patients with locally advanced gastro-oesophageal cancers are unable to complete adjuvant 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy, raising questions about its therapeutic utility. The aim of this study was examine whether pathological response neoadjuvant FLOT can guide use. Methods Patients non-metastatic adenocarcinoma who received underwent surgery from 1 January 2017 2022 43 hospitals across 12 countries were analysed....
Objective: To investigate if prolonged TTS after completed nCRT improves postoperative outcomes for esophageal and esophagogastric junction cancer. Summary of Background Data: has traditionally been 4–6 weeks nCRT. However, the optimal timing is not known. Methods: A multicenter clinical trial was performed with randomized allocation or 10–12 weeks. The primary endpoint this sub-study overall complications defined as Clavien-Dindo grade II-V. Secondary endpoints included complication...
The globally dominant treatment with curative intent for locally advanced esophageal squamous cell carcinoma (ESCC) is neoadjuvant chemoradiotherapy (nCRT) subsequent esophagectomy. This multimodal leads to around 60% overall 5-year survival, yet impaired post-surgical quality of life. Observational studies indicate that curatively intended chemoradiotherapy, so-called definitive (dCRT) followed by surveillance the primary tumor site and regional lymph node stations surgery only when needed...
IntroductionGastric cancer often presents in advanced stage with a significant risk for peritoneal dissemination. Staging laparoscopy can be used to detect carcinomatosis (PC+) and free cells lavage cytology (CY+). The current study aimed present the outcomes of staging prognosis PC+ CY+ Swedish high-volume center.Materials methodsA cohort including all consecutive patients locally gastric who underwent between February 2008 October 2022. findings were categorized as PC+, PC-CY+ (positive...
Abstract Background Randomized trials have shown that neoadjuvant treatment improves survival in the curative of oesophageal and gastro-oesophageal junction cancer. Results from population-based observational studies are, however, sparse ambiguous. Methods This prospective cohort study included all patients who had oesophagectomy for cancer Sweden, excluding clinical T1 N0, recorded National Register Oesophageal Gastric Cancer, 2006–2014. Patients were stratified into three groups: surgery...
There are few data comparing health-related quality of life (HRQoL) after neoadjuvant chemotherapy alone (nCT) compared with chemoradiotherapy (nCRT) in patients oesophageal cancer.In the NeoRes trial, were assigned randomly a 1 : ratio to receive either cisplatin 100 mg/m2 on day and an infusion 750 mg per m2 5-fluorouracil over 24 h days 1-5 three 21-day cycles or same regimen, but addition 40 Gy radiotherapy (nCRT). HRQoL collected at baseline, therapy 1, 3 5 years surgery. The European...
The aim of this study was to investigate long-term HRQOL and symptom evolution in disease free patients up 20 years after esophagectomy.